Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 32.4474
- Book/Share 0.8269
- PB 230.9481
- Debt/Equity 49.2176
- CurrentRatio 0.7602
- ROIC 0.1793
- MktCap 327649536000.0
- FreeCF/Share 8.7019
- PFCF 21.2967
- PE 78.1755
- Debt/Assets 0.5133
- DivYield 0.0344
- ROE 0.9559
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
| Resumed | ABBV | BofA Securities | -- | Neutral | -- | $191 | Dec. 10, 2024 |
| Downgrade | ABBV | Daiwa Securities | Outperform | Neutral | -- | $180 | Dec. 5, 2024 |
| Initiation | ABBV | Bernstein | -- | Market Perform | -- | $203 | Oct. 17, 2024 |
News
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.
Read More
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Here's Why AbbVie (ABBV) is a Strong Value Stock
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
AbbVie says blood cancer drug fails late-stage trial
Published: June 16, 2025 by: Reuters
Sentiment: Negative
AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of overall survival in a late-stage trial.
Read More
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
Published: June 16, 2025 by: PRNewsWire
Sentiment: Neutral
NORTH CHICAGO, Ill. , June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772.
Read More
Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ's approval has sparked competition among other pharmaceutical companies in the giant cell arteritis market. The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form …
Read More
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
Published: June 11, 2025 by: PRNewsWire
Sentiment: Neutral
MAVYRET® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV)* With this approval, providers can now treat HCV patients immediately at the time of diagnosis HCV is a curable condition, but patients can often go undiagnosed.1 If left untreated, people with acute HCV could progress to chronic disease, including liver-related complications, such as cirrhosis or liver cancer1 The approval supports global clinical guidelines to advance testing and treatment for people with HCV regardless of chronicity, and supports public health goals for disease elimination NORTH CHICAGO, Ill. , …
Read More
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
Read More
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
Read More
Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc. (ABBV)
Published: June 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Read More
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
Read More
Bert's May 2025 Dividend Income Summary
Published: June 03, 2025 by: Seeking Alpha
Sentiment: Negative
Our dividend income dropped by 15% in May. We had Healthpeak Properties change the structure of its dividend. June will be a very exciting month and I cannot wait to see the dividend distributions for our ETFs, especially SCHD.
Read More
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals. As the only company with three approved products designed to meet patient needs across the spectrum of migraine, AbbVie is committed to supporting the migraine community beyond treatment.
Read More
AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral
NORTH CHICAGO, Ill. , June 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025.
Read More
Put Cash To Work: 2 Magnificent Dividends I'm Betting On
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, robust margins, and a 32-year dividend growth streak, justifying its GARP valuation. AbbVie is rapidly replacing Humira revenue with high-growth drugs, maintains industry-leading margins, and delivers a 3.5% yield with double-digit EPS growth potential.
Read More
Final Trades: JPMorgan, Meta, Abbvie and Gap
Published: May 30, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc.(ABBV)
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Read More
AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.
Read More
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
Lost Money on Cerevel Therapeutics Holdings, Inc. (ABBV)? Urged to Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=150335&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV
Published: May 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
Read More
Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc. (ABBV) of a Class Action Lawsuit and an Upcoming Deadline
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
Read More
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Read More
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=149485&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc. (ABBV) Shareholders
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Read More
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class Action - ABBV
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
The Only 5 ETFs You Need to Build Wealth for Retirement
Published: May 19, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Dividend stocks are a foundational building block for creating a retirement portfolio, offering a reliable income stream and potential for capital appreciation.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Mr. Robert A. Michael CPA
- Employees 55000